Our Programs
Standalone Immunotherapeutics
Combination Compatibility
Advancing novel therapies for B-Cell ALL and hard-to-treat solid tumors, engineered for potent, comprehensive anti-tumour responses and mechanistic safety profiles.
Designed for seamless integration into existing treatment regimens, our modular assets enhance efficacy and expand therapeutic reach through strategic partnerships.
Preclinical Validation & Scalable Manufacturing
Our immune reprogramming logic is rigorously validated through advanced cellular assays, demonstrating robust cytotoxicity and precise target engagement across diverse oncology models.
Clinical-grade manufacturing protocols are optimized for scalability and reproducibility, ensuring consistent product quality and reliable supply for future trials and commercialization.
Partner with AUCIDUS
Connect with our business development team to explore licensing opportunities and strategic collaborations across our advanced oncology pipeline.